September 23, 2024Media Coverage
Original article: Genprex – Developing Novel Gene Therapies in Cancer with Tumor Suppressor Genes and Diabetes Converting Alpha Cells into Beta Cells to Produce Insulin (CEO CFO Magazine)
September 23, 2024Press Releases
Company’s CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs AUSTIN, Texas — (Sept. 23, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in […]
September 19, 2024Press Releases
Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma AUSTIN, Texas — (Sept. 19, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company’s […]
September 9, 2024Press Releases
Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma AUSTIN, Texas — (Sept. 9, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected […]
September 4, 2024Press Releases
Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes AUSTIN, Texas — (Sept. 4, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced […]
September 3, 2024Press Releases
Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes AUSTIN, Texas — (Sept. 3, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held […]
Designed and Secured by Barsec